Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Prime Medicine, Inc. ( (PRME) ) just unveiled an update.
On July 30, 2025, Prime Medicine, Inc. entered into an Underwriting Agreement with TD Securities (USA) LLC and BMO Capital Markets Corp. for a public offering of 38,000,000 shares of its common stock at $3.30 per share. The company expects to raise approximately $120.2 million from this offering, which will be used to fund research and development for its Wilson’s Disease and Alpha-1 Antitrypsin Deficiency programs, as well as for general corporate purposes. The offering is anticipated to close around August 1, 2025, and is made under the company’s shelf registration statement filed with the SEC.
The most recent analyst rating on (PRME) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Prime Medicine, Inc. stock, see the PRME Stock Forecast page.
Spark’s Take on PRME Stock
According to Spark, TipRanks’ AI Analyst, PRME is a Neutral.
Prime Medicine, Inc. faces significant financial hurdles with ongoing losses and dependency on external funding. While recent technical indicators show potential for recovery, the stock remains under pressure. The promising preclinical results offer a positive long-term outlook, but the current valuation and financial performance weigh heavily on the overall score.
To see Spark’s full report on PRME stock, click here.
More about Prime Medicine, Inc.
Average Trading Volume: 3,691,742
Technical Sentiment Signal: Buy
Current Market Cap: $515.1M
For a thorough assessment of PRME stock, go to TipRanks’ Stock Analysis page.